SML2612
KDS2010
≥98% (HPLC)
别名:
(S)-2-(((4′-Trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate, (S)-2-((4′-(Trifluoromethyl)biphenyl-4-yl)methylamino)propanamide methanesulfonate
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
H2O: 2 mg/mL, clear
储存温度
2-8°C
生化/生理作用
KDS2010 is a highly selective, substrate-competitive, potent and reversible monoamine oxidase MAO-B inhibitor (IC50 = 7.6 nM/MAO-B vs >100 μM/MAO-A; little affinity toward 99 kinases and 84 non-kinase targets) with excellent ADME/Tox profiles (IC50 >10 μM/P450, >50 μM/hERG), brain permeability and oral availability ([rat F = 123.5%; 10 mg/kg p.o.). KDS2010 restores memory impairments in APP/PS1 mice following either short- or long-term treatment (3-d or 4-wk 10 mg/kg/day p.o.) without aberrant GABA levels observed with prolonged irreversible inhibition by selegiline (MAO-B/MAO-A IC50 = 10 nM/1.5 μM) due to compensatory diamine oxidase (DAO) induction.
Orally active, brain-penetrant, highly selective, potent, reversible MAO-B inhibitor without aberrant GABA levels observed with long-term selegiline treatment in AD mice.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
Jong-Hyun Park et al.
Science advances, 5(3), eaav0316-eaav0316 (2019-03-25)
Monoamine oxidase-B (MAO-B) has recently emerged as a potential therapeutic target for Alzheimer's disease (AD) because of its association with aberrant γ-aminobutyric acid (GABA) production in reactive astrocytes. Although short-term treatment with irreversible MAO-B inhibitors, such as selegiline, improves cognitive
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持